Cellectar Biosciences (CLRB) News Today $4.73 +0.02 (+0.42%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$4.70 -0.03 (-0.53%) As of 08/8/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLRB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025August 7 at 8:05 AM | globenewswire.comAll You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to BuyJuly 15, 2025 | msn.comCLRB - Cellectar Biosciences Inc Dividends - MorningstarJuly 4, 2025 | morningstar.comMChad J. Kolean Acquires 5,000 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) StockJuly 4, 2025 | insidertrades.comCellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option - MorningstarJuly 4, 2025 | morningstar.comMCellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering - MorningstarJuly 2, 2025 | morningstar.comMCellectar Biosciences prices $6 million public offeringJuly 2, 2025 | investing.comCellectar Biosciences, Inc. Announces Pricing of Underwritten Public Offering for Approximately $6 Million - NasdaqJuly 2, 2025 | nasdaq.comCellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment OptionJuly 2, 2025 | globenewswire.comCellectar Biosciences Shares Drop After $6M Public Offering PricesJuly 1, 2025 | marketwatch.comCellectar Biosciences, Inc. Announces Pricing of Underwritten Public Offering for Approximately $6 MillionJuly 1, 2025 | quiverquant.comQCellectar Biosciences Announces Pricing of $6 Million Underwritten Public OfferingJuly 1, 2025 | globenewswire.comCellectar Biosciences enacts one-for-thirty reverse stock split on NasdaqJune 27, 2025 | uk.investing.comCellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply AgreementJune 26, 2025 | theglobeandmail.comCellectar Biosciences, Inc. (CLRB) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comCellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply AgreementJune 26, 2025 | globenewswire.comCellectar Biosciences (NASDAQ:CLRB) Shares Gap Down - Time to Sell?June 24, 2025 | marketbeat.comCellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)June 24, 2025 | globenewswire.comCellectar Biosciences, Inc.: Cellectar Biosciences Announces One-for-Thirty Reverse Stock SplitJune 19, 2025 | finanznachrichten.deCellectar Biosciences, Inc. Announces One-for-Thirty Reverse Stock Split Effective June 24, 2025June 18, 2025 | quiverquant.comQCellectar Biosciences Announces One-for-Thirty Reverse Stock SplitJune 18, 2025 | globenewswire.comCellectar Biosciences Reports Promising Initial Results from CLOVER-2 Phase 1 Trial of Iopofosine I 131 for Pediatric High-Grade GliomaJune 13, 2025 | nasdaq.comCellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade GliomaJune 11, 2025 | globenewswire.comCellectar Biosciences stock soars on FDA breakthrough designationJune 5, 2025 | investing.comCellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq RulesJune 5, 2025 | globenewswire.comFDA Designation Sparks Rally For This BiotechJune 4, 2025 | msn.comWhat's Behind Cellectar Biosciences' Stock Surge? FDA Update ExplainedJune 4, 2025 | finance.yahoo.comCellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)June 4, 2025 | globenewswire.comMaxim Group Downgrades Cellectar Biosciences (CLRB)May 15, 2025 | msn.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2025 Earnings Call TranscriptMay 14, 2025 | insidermonkey.comCellectar Biosciences Inc (CLRB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...May 14, 2025 | finance.yahoo.comCellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comCellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 13, 2025 | globenewswire.comInsights Ahead: Cellectar Biosciences's Quarterly EarningsMay 12, 2025 | benzinga.comCellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025May 7, 2025 | globenewswire.comCellectar explores strategic options to enhance shareholder valueMay 2, 2025 | uk.investing.comCellectar Announces Plan to Explore Strategic AlternativesApril 30, 2025 | globenewswire.comCellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call TranscriptMarch 15, 2025 | seekingalpha.comOppenheimer Keeps Their Hold Rating on Cellectar Biosciences (CLRB)March 14, 2025 | markets.businessinsider.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | insidermonkey.comQ4 2024 Cellectar Biosciences Inc Earnings CallMarch 13, 2025 | uk.finance.yahoo.comCellectar Biosciences reports FY24 EPS ($1.40), consensus ($1.57)March 13, 2025 | markets.businessinsider.comCellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate UpdateMarch 13, 2025 | globenewswire.comCellectar Biosciences to Present at the 37th Annual Roth ConferenceMarch 11, 2025 | markets.businessinsider.comCellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025March 5, 2025 | globenewswire.comCellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | globenewswire.comCellectar faces Nasdaq delisting over share price ruleFebruary 3, 2025 | msn.comCellectar Biosciences files to sell 19.22M shares of common stock for holdersJanuary 30, 2025 | markets.businessinsider.comCellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare ConferenceJanuary 13, 2025 | finance.yahoo.comCellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare ConferenceJanuary 12, 2025 | globenewswire.com Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address CLRB Media Mentions By Week CLRB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLRB News Sentiment▼0.000.50▲Average Medical News Sentiment CLRB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLRB Articles This Week▼11▲CLRB Articles Average Week Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KPTI News XLO News RANI News MRSN News AKTX News ESLA News SNYR News ITRM News DYAI News CLSD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLRB) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
